<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213160</url>
  </required_header>
  <id_info>
    <org_study_id>D2610C00002</org_study_id>
    <nct_id>NCT01213160</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient</brief_title>
  <official_title>A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to explore the safety and tolerability of AZD4547 in
      Japanese patients with advanced solid malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics
      and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients with
      Advanced Solid Malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events (based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)general examination</measure>
    <time_frame>General examination prior to IP administration in treatment cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0)general examination</measure>
    <time_frame>General examination on day 1 in cycle 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0)general examination</measure>
    <time_frame>General examination day 21 in cycle 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), laboratory values</measure>
    <time_frame>Laboratory assessment prior to IP administration in all treatment cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), laboratory values</measure>
    <time_frame>Laboratory assessment on day 1 in cycle 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), laboratory values</measure>
    <time_frame>Laboratory assessment day 1 cycle 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), laboratory values</measure>
    <time_frame>Laboratory assessment day 8 cycle 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), laboratory values</measure>
    <time_frame>Laboratory assessment day 15 cycle 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), laboratory values</measure>
    <time_frame>Laboratory assessment day 21 cycle 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements</measure>
    <time_frame>Vital sign measurements prior to IP administration in all treatment cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements</measure>
    <time_frame>Vital sign measurements day 1 in cycle 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements</measure>
    <time_frame>Vital sign measurements day 2 in cycle 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements</measure>
    <time_frame>Vital sign measurements day 8 in cycle 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements</measure>
    <time_frame>Vital sign measurements day 21 in cycle 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), left ventricular ejection fraction (LVEF)</measure>
    <time_frame>LVEF prior to study administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), LVEF</measure>
    <time_frame>LVEF on day 21 in cycle 1.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), eye examination</measure>
    <time_frame>Eye examination prior to study administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 4.0), eye examination</measure>
    <time_frame>Eye examination on day 21 in cycle 1.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define the maximum tolerated dose (MTD) if possible or biological effective dose.</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the pharmacokinetics (PK) of AZD4547and metabolite in Japanese patients with advanced solid malignancies when given AZD4547 orally.</measure>
    <time_frame>Schedule of PK assessment 1. AZD4547; blood Cycle0-day1 -day21; 27 point 2. AZD4547 metabolite; blood Cycle1-day21; 1 poin 3. AZD4547; urine Cycle1-day21; 1 point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain a preliminary assessment of the anti-tumour effect of AZD4547 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) criteria v1.1.</measure>
    <time_frame>Schedule of CT/MRI etc-screeing-cycle1 day21-every 6 weeks-the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cancer</condition>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>AZD4547</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4547</intervention_name>
    <description>film coated tablet, PO, twice daily</description>
    <arm_group_label>AZD4547</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Japanese patients with advanced solid malignancies Over 25 years old Relatively good
        overall health other than cancer

        Exclusion Criteria:

        - Poor bone marrow function (not producing enough blood cells). Poor liver or kidney
        function. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
        swallow the IP or previous significant bowel resection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>150 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Stockman</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hideo Saka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital Organisation Nagoya Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yasuo Takahashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital OrganisationHokkaido Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1282&amp;filename=D2610C00002_CSR_Synopsis.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2010</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>cancer</keyword>
  <keyword>solid tumours</keyword>
  <keyword>advanced solid malignancies</keyword>
  <keyword>dose escalation</keyword>
  <keyword>FGFR TKI</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

